Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma

Fig. 1

Study design. All patients received three dose regimens; each was separated by a 2-week washout period. Patients in the 5 μg total daily dose group received one of six possible sequences of olodaterol 2.5 μg BID, 5 μg QD and placebo. Patients in the 10 μg total daily dose group received one of six possible sequences of olodaterol 5 μg BID, 10 μg QD and placebo. Patients continued taking ICS throughout the study, with posology determined by former use. If administration of ICS and study treatment coincided, patients were to take study treatment followed by ICS

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us